drugset / Trial / NCT02290210
Phase 2 Study of URC102 to Assess the Efficacy and Safety in Gout Patients
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to assess safety, PK/PD and Urate Lowering Effect of URC102 in gout patients with hyperuricemia
Timeline
- Start
- 2014-07-24
- Primary completion
- 2014-12-02
- Completion
- 2015-08-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | URC102 | Unknown | 0.25 mg | — |
| Subject | URC102 | Unknown | 0.5 mg | — |
| Subject | URC102 | Unknown | 1 mg | — |
| Subject | URC102 | Unknown | 2 mg | — |